Welcome to our dedicated page for CURANEX PHARMACEUTICALS news (Ticker: CURX), a resource for investors and traders seeking the latest updates and insights on CURANEX PHARMACEUTICALS stock.
Curanex Pharmaceuticals Inc (NASDAQ: CURX) is a developmental-stage biotechnology company headquartered in Jericho, New York, that focuses on discovering and developing botanical drugs for inflammatory diseases. The Curanex news page on Stock Titan aggregates company press releases, market announcements, and regulatory disclosures so readers can follow how its drug development and corporate activities evolve over time.
News about Curanex often centers on its lead botanical candidate Phyto-N, a single-plant extract with anti-inflammatory properties that the company is advancing for moderate to severe ulcerative colitis and other inflammatory indications. Updates may cover preclinical research progress, plans for FDA-required GLP toxicology and pharmacokinetic studies, and steps toward an Investigational New Drug (IND) submission and Phase I clinical trials.
Investors can also find coverage of capital markets events, such as the pricing and closing of Curanex’s initial public offering on the Nasdaq Capital Market and the exercise of underwriters’ over-allotment options. Additional news items may highlight unregistered sales of equity securities, related-party financing transactions and their repayment, and the company’s engagement of Strategic Investor Relations, LLC to enhance investor communications.
Regulatory and listing-related developments appear in the news flow as well, including SEC filings and Nasdaq notifications. For example, Curanex has reported a Nasdaq notice regarding the minimum bid price requirement and a Form 12b-25 explaining a brief delay in filing a Quarterly Report on Form 10-Q. By reviewing these updates in one place, readers can track how Curanex manages its listing status, financing, and pipeline milestones.
Bookmark this page to monitor Curanex’s official announcements, SEC-related news, and key developments in its botanical drug programs for inflammatory diseases.
Curanex (NASDAQ: CURX) is expanding its development pipeline to add cancer cachexia as a new core indication, citing a large unmet need and commercial opportunity. The company notes the global market was about $2.54 billion in 2024, projected to $3.90 billion by 2033, and plans to evaluate development paths while advancing lead program Phyto-N.
Curanex (Nasdaq: CURX) provided a business update alongside its 2025 Form 10-K, reporting operational progress toward a planned IND submission for Phyto-N in Q4 2026. The company completed a pilot-scale GMP batch, finished dose-range finding toxicology in rats and dogs, filed a PCT application in March 2025, and says it has funding for at least twelve months to support near-term IND-enabling activities.
Curanex (Nasdaq: CURX) completed a 28-day repeat-dose dose-range finding toxicology study of lead botanical candidate Phyto-N in rats and dogs, finding no toxicological findings at the maximum feasible dose. The highest dose equated to ~6x the proposed clinical dose in dogs and ~4x in rats.
The MFD will anchor pivotal GLP toxicology studies required for a planned IND submission targeted for Q4 2026. Phyto-N has >30 years of prior human use in China.
Curanex (NASDAQ: CURX) appointed Dr. Taku Kambayashi and Dr. Selvakumar Subbian to its Scientific Advisory Board to support immunology, infectious disease research, IND preparation and intellectual property strategy. The company said it will name one additional advisor pending employer approval.
Curanex targets completion of FDA-required preclinical studies and an IND submission with clinical trials planned for Q4 2026.
Curanex (Nasdaq: CURX) appointed Dr. Daniel Pascheles and Dr. Nicholas A. Meanwell to its Scientific Advisory Board on March 11, 2026. The advisors bring a combined >75 years of pharmaceutical experience and will advise on commercial strategy, product portfolio development, and go‑to‑market decisions.
Dr. Pascheles previously led global competitive intelligence at Merck and held senior roles at Aventis; Dr. Meanwell led drug discovery at Bristol Myers Squibb and advanced 33 clinical candidates, including multiple approved medicines.
Curanex (NASDAQ: CURX) announced formation of a five-member Scientific Advisory Board on March 5, 2026 to support R&D, upcoming clinical trials, technical development, intellectual property, commercialization and strategic value creation.
The board will include two industry commercial experts and three academic researchers; full member names will be disclosed shortly.
Curanex (Nasdaq: CURX) completed a GMP-compliant pilot-scale batch of its lead botanical candidate Phyto-N, advancing CMC readiness to support GLP toxicology, pharmacokinetic, and other IND-enabling studies. The company continues to target an IND submission for ulcerative colitis in Q4 2026.
Completed CMC activities include QC methods for raw materials, lab-scale process optimization, and GMP pilot production; non-GLP safety and metabolism studies showed no treatment-related toxicity and minimal interspecies variability.
Curanex Pharmaceuticals (Nasdaq: CURX) engaged Strategic Investor Relations, LLC on October 22, 2025 to strengthen investor communications and visibility. The firm will support outreach, refine messaging, and highlight Curanex’s botanical drug pipeline targeting ulcerative colitis, atopic dermatitis, and gouty arthritis.
The company's lead Ulcerative Colitis candidate is on track for an IND submission in 2026, and management emphasized regulatory compliance with the FDA and a development approach informed by over 30 years of clinical evidence in China.
Curanex Pharmaceuticals (NASDAQ:CURX), a developmental stage pharmaceutical company, announced the full exercise of the over-allotment option by lead underwriter Dominari Securities LLC following its IPO. The underwriters purchased an additional 562,500 shares at $4.00 per share, raising an extra $2.25 million.
The total gross proceeds from the IPO now amount to $17.25 million through the issuance of 4,312,500 total shares. The offering was led by Dominari Securities LLC, with Pacific Century Securities and Revere Securities as co-underwriters. The registration statement became effective on August 12, 2025.
Curanex Pharmaceuticals (NASDAQ:CURX), a developmental stage pharmaceutical company focused on botanical drugs for inflammatory diseases, has successfully completed its Initial Public Offering (IPO). The company raised $15 million in gross proceeds through the offering of 3,750,000 shares at $4.00 per share.
Trading of CURX shares commenced on the Nasdaq Capital Market on August 26, 2025. The underwriters, led by Dominari Securities LLC, have a 45-day option to purchase up to 562,500 additional shares at the public offering price, less underwriting discounts and expenses.